|
|
The Cooper Companies Inc (NASDAQ: COO) |
|
Price: $99.2800
$0.20 
0.202%
|
| Day's High:
| $100.25
| Week Perf:
| -3.83 %
|
| Day's Low: |
$ 98.58 |
30 Day Perf: |
-5.64 % |
| Volume (M): |
1,104 |
52 Wk High: |
$ 112.38 |
| Volume (M$): |
$ 109,559 |
52 Wk Avg: |
$97.20 |
| Open: |
$99.35 |
52 Wk Low: |
$84.76 |
|
|
| Market Capitalization (Millions $) |
19,871 |
| Shares
Outstanding (Millions) |
200 |
| Employees |
14,000 |
| Revenues (TTM) (Millions $) |
3,892 |
| Net Income (TTM) (Millions $) |
392 |
| Cash Flow (TTM) (Millions $) |
8 |
| Capital Exp. (TTM) (Millions $) |
374 |
The Cooper Companies Inc
The Cooper Companies Inc. is a prominent American medical device company with a focus on ophthalmology and fertility. Established in 1958 by Martin Cooper, the company initially set out to produce contact lenses under the name eCooper Laboratories. Over the decades, it has grown substantially and now serves customers in more than 100 countries globally.
Business Segments
The Cooper Companies operates primarily through two segments:
1. CooperVision: This segment encompasses the companys vision care products. The CooperVision product line includes a variety of soft contact lenses, such as silicone hydrogel lenses, toric lenses for astigmatism, multifocal lenses for presbyopia, and lens care solutions. Key brands within this segment include Biofinity, Avaira, Proclear, and Clariti. The lenses are designed to address various eye conditions like myopia, hyperopia, and astigmatism.
2. CooperSurgical: This segment focuses on fertility and encompasses products and services aimed at assisting couples in becoming pregnant. CooperSurgical develops and markets medical devices and consumables for assisted reproductive technologies, such as in-vitro fertilization (IVF), positioning itself as a leader in this field with significant market presence in the United States, Europe, and Japan.
Strategic Growth and Acquisitions
The Cooper Companies has strategically expanded its product offerings and market reach through various acquisitions over the years. Notable acquisitions include:
- In 2014, the acquisition of Sauflon Pharmaceuticals, a British contact lens manufacturer, which bolstered CooperVisions presence in Europe.
- In 2017, the acquisition of the global women's health business assets from Teva Pharmaceuticals, enhancing CooperSurgicals position in the women's health market.
Customer Base and Operations
The company serves a diverse customer base, including eye care professionals, hospitals, clinics, and retail outlets. Additionally, it has developed an e-commerce platform that allows patients to purchase contact lenses directly from The Cooper Companies.
Corporate Structure and Workforce
Based in San Ramon, California, The Cooper Companies has a significant global presence with manufacturing and distribution facilities in the United States, Europe, and Asia. The company employs over 12,000 individuals worldwide, highlighting its expansive operations and commitment to innovation within the medical device sector.
Financial Performance
As of its most recent financial reports, The Cooper Companies has demonstrated strong growth, with reported revenues in the vicinity of $2.6 billion for the fiscal year 2020, reflecting its solid position in both the ophthalmic and fertility markets.
In summary, The Cooper Companies Inc. continues to evolve as a key player in the medical device industry, with a dual focus on enhancing eye care through innovative vision solutions and supporting fertility through advanced reproductive technologies.
Company Address: 6101 Bollinger Canyon Road San Ramon 94583 CA
Company Phone Number: 460-3600 Stock Exchange / Ticker: NASDAQ COO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Merger and Acquisition
Published Thu, Aug 1 2024 8:15 PM UTC
CooperCompanies Expands Surgical Portfolio with Acquisition of obp Surgical
On August 1, 2024, CooperCompanies (Nasdaq: COO), a leading player in the medical equipment and supplies sector, announced a strategic acquisition set to strengthen its CooperSurgical business unit. The company has acquired obp Surgical for approximately $100 million. This move comes as part of C...
|
| Announcement
Published Thu, May 30 2024 8:15 PM UTC
CooperCompanies Announces Impressive Second Quarter 2024 Results, Solidifying its Position as a Global Leader in Medical DevicesSAN RAMON, Calif., May 30, 2024 - CooperCompanies (Nasdaq: COO), a prominent player in the medical device industry, has unveiled its financial results for the fiscal second quarter that concluded on April 30, 2024. The latest figures showcase the co...
|
| Product Service News
Published Thu, May 23 2024 8:15 PM UTC
CooperCompanies 2023 Environmental, Social, and Governance Report Highlights Efforts that Benefit People and the PlanetSAN RAMON, Calif., May 23, 2024 - CooperCompanies (Nasdaq: COO), a global leader in medical devices, today unveiled its highly anticipated 2023 Environmental, Social, and Governance (ESG) Report. This comprehensive report is a testament to the company's unwa...
|
| The Cooper Companies Inc
The Cooper Companies Inc. (COO), a global medical equipment and supplies company, recently announced its financial results for the fiscal fourth quarter and full year ending October 31, 2023. While the company reported some positive figures, there are concerns that cast doubt on its long-term prospects.
The company's Chief Operating Officer (COO) stated that the earnings per share (EPS) is expected to increase by a remarkable 27.72% to $1.69 in the financial period ending October 31, 2023. Although this seems like positive news, it is important to note that the EPS decreased by -1.37% from $1.71 per share in the previous reporting season. This decline should not be overlooked as it indicates a potential trend of declining profitability.
|
| The Cooper Companies Inc
Medical Equipment & Supplies Company, The Cooper Companies Inc, experienced a decline in earnings per share (EPS) despite a rise in revenue for the financial period ending on July 31, 2023. Although revenue increased by a significant 10.268% to $930.00 million compared to the previous year, income fell by -13.64% to $1.71 per share.
Despite the decline in EPS, the company's revenue surge in the third quarter of 2023 surpassed its industry peers, which only experienced a 4.05% overall business increase during the same period. Comparing to the previous reporting period, EPS showed impressive growth of 113.75% from $0.80 per share, while revenue improved by 5.995% from $877.40 million.
However, net earnings declined by -13.31% to $85.300 million at the end of July, compared to $98.400 million in the same period a year earlier. The Cooper Companies Inc focused on improving sales during the financial period, leading to a net margin decrease to 9.17%. Additionally, there has been a noticeable buildup in inventories, with inventories and supplies reaching $723.6 million, higher than the previous and corresponding quarter of the previous year.
On a positive note, operating earnings rose by 7.82% to $151.6 million. The increase in accounts receivable also indicates rising demand, with a value of $629.9 million, higher than the preceding quarter.
Looking into the future performance, The Cooper Companies Inc shares recorded a decline of -0.19% over the past five trading days, resulting in a year-to-date performance of 11.63%. The shares are currently 7.1% short of the 52-week highInvestors will be eagerly waiting to see the next financial numbers from The Cooper Companies Inc, which are expected to be reported on December 08, 2023. With a focus on improving sales and a noticeable buildup in inventories and accounts receivable, the company may be positioning itself for future growth despite the recent decline in EPS.
|
| Per Share |
Current |
| Earnings (TTM) |
1.94 $ |
| Revenues (TTM) |
19.44 $
|
| Cash Flow (TTM) |
0.04 $ |
| Cash |
0.54 $
|
| Book Value |
40.39 $
|
| Dividend (TTM) |
0.01 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.94 $
|
| Revenues (TTM) |
19.44 $ |
| Cash Flow (TTM) |
0.04 $ |
| Cash |
0.54 $
|
| Book Value |
40.39 $ |
| Dividend (TTM) |
0.01 $ |
|
|
|
|
7.3%